PWE-003 Mdm2 t309g polymorphism and risk of colorectal cancer. (17th June 2017)

• Record Type: Journal Article
• Authors: Aggarwal, N; Donald, ND; Malik, S; Selvendran, SS; McPhail, M; Monahan, KJ
• Is Part Of: Gut. Volume 66(2017)Supplement 2
• Page Start: A126
• Page End: A127
• Publication Date: 2017-06-17
• Subjects: COLORECTAL CANCER -- GENETIC SUSCEPTIBILITY -- GENOTYPE -- Polymorphism; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2017-314472.248
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: Murine double minute 2 (MDM2) is an E3 ubiquitin-protein ligase that mediates cell cycle arrest by negatively regulating the tumour suppressor gene p53. Polymorphisms have been thought to be associated with colorectal cancer (CRC), however results have been largely inconclusive. A meta-analysis of MDM2 T309G (rs2279744) was conducted to clarify and assess whether any association could be found. Method: A systematic literature review of the Pubmed and HuGENet databases was conducted and studies were included/excluded based on pre-specified criteria. The per allele model was used to assess risk by calculating pooled odds ratios with 95% confidence intervals. Publication bias was investigated using a funnel plot. Statistical analysis was conducted using the R program (version 3.2.4). Results: A total of 135 studies were screened and 6 case control studies were included with 3553 cases and 5781 controls. No association was found between MDM2 T309G and CRC (OR=1.25; 95% CI 0.97–1.62). The funnel plot showed that publication bias was present. Conclusion: This meta-analysis suggests that MDM2 T309G polymorphism is not associated with risk of CRC and should not be evaluated as part of a patient risk assessment. Future studies with larger and more varied ethnicities would allow more accurate assessment of the association between MDM2 T390G and CRC risk. Disclosure of Interest: None Declared